Predictors of death within 6 months after non-ST elevation myocardial infarction in postCOVID-19 patients.
Profilakticheskaya Meditsina
; 25(4):47-54, 2022.
Article
in Russian
| Academic Search Complete | ID: covidwho-1811636
ABSTRACT
Objective. To investigate predictors of death within six months of non-ST elevation myocardial infarction (NSTEMI) in postCOVID-19 patients. Material and methods. Outcomes were analyzed in 185 patients treated for NSTEMI at the Demikhov City Clinical Hospital from July 2020 to March 2021. Six months after discharge from the hospital, telephone interviews were conducted with treated patients, and in the absence of the possibility of personal contact, with their next of kin. During the survey, an assessment was made of the vital status (alive/dead), the presence of repeated hospitalizations and their causes. In the event of a patient’s death, the cause of death was clarified on the basis of information received from relatives or from a unified medical information analytical system. Results. Overall mortality within 6 months after NSTEMI was 9.7% (n=18), in the COVID(+) group — 13.8% (n=13), in the COVID(–) group — 5.5% (n=5), p=0.0558. By causes of death, both groups are comparable (p>0.05). Median survival in patients in the COVID(+) group was 5.4 months (95% CI 5.1-5.7) and 5.9 months (95% CI 5.8-6.0) in patients in the COVID(–) group (χ² =5.27;p=0.0217). The deceased and survivors were comparable in terms of gender and age (p>0.05). The deceased patients had lower baseline values of SpO2, hemoglobin, glomerular filtration rate (GFR) and had a higher score on the Syntax scale, C-reactive protein (CRP), creatinine (p<0.05). Patients had a history of COVID-19 in 72.2% (n=13) of lethal cases (p=0.0554). In 72.2% (n=13) of patients with a fatal outcome, multi-vessel coronary artery disease was noted (p<0.0001). With the development of NSTEMI within 28 days of COVID-19 disease, there was an increase in the risk of death (RR 33.2;p<0.0001). Predictors of the development of a lethal outcome after 6 months were an increase in the titer of IgG to SARS-CoV-2 ≥ 234.9 U/l, CRP ≥ 17.3 mg/l, a decrease in prothrombin time <9.5 s, GFR < 46.9 ml/l min/1.73 m² . Conclusion. Patients who survived COVID-19 showed a trend towards a higher incidence of deaths within 6 months. The development of a non-ST elevation myocardial infarction within 28 days of the onset of COVID-19 symptoms was accompanied by a significant increase in the chances of death within 6 months. A significant impact on the risk of death within 6 months was exerted by an increased level of C-reactive protein and IgG to SARS-CoV-2, a decrease in prothrombin time and glomerular filtration rate. (English) [ FROM AUTHOR] Цель иÑÑледованиÑ. Изучить предикторы летального иÑхода в течение 6 меÑÑцев поÑле инфаркта миокарда без подъема Ñегмента ST (ИМбпST) у пациентов, перенеÑших COVID-19. Материал и методы. У 185 пациентов проанализированы результаты Ð»ÐµÑ‡ÐµÐ½Ð¸Ñ Ð¿Ð¾ поводу ИМбпST в ГБУЗ «ГКБ имени Ð’.П. Демихова ДЗМ». Ð’ иÑÑледование включены пациенты, выбывшие из Ñтационара в период Ñ Ð¸ÑŽÐ»Ñ 2020 г. по март 2021 г. Через 6 Ð¼ÐµÑ Ð¿Ð¾Ñле выпиÑки из Ñтационара проведено телефонное интервьюирование пациентов (или ближайших родÑтвенников при отÑутÑтвии возможноÑти личного контакта). Во Ð²Ñ€ÐµÐ¼Ñ Ð¾Ð¿Ñ€Ð¾Ñа оÑущеÑтвлÑли оценку жизненного ÑтатуÑа (жив/умер), Ð½Ð°Ð»Ð¸Ñ‡Ð¸Ñ Ð¿Ð¾Ð²Ñ‚Ð¾Ñ€Ð½Ñ‹Ñ… гоÑпитализаций и их причин. Ð’ Ñлучае Ñмерти больного уточнÑли причину Ñмерти по информации, полученной от родÑтвенников или из Единой медицинÑкой информационно-аналитичеÑкой ÑиÑтемы. Результаты. ÐžÐ±Ñ‰Ð°Ñ Ð»ÐµÑ‚Ð°Ð»ÑŒÐ½Ð¾ÑÑ‚ÑŒ в течение 6 Ð¼ÐµÑ Ð¿Ð¾Ñле ИМбп ST ÑоÑтавила 9,7% (n=18), в группе COVID(+) — 13,8% (n=13), в группе COVID(–) — 5,5% (n=5), p=0,0558. По причинам Ñмерти обе группы между Ñобой ÑопоÑтавимы (p>0,05). Средний Ñрок Ð´Ð¾Ð¶Ð¸Ñ‚Ð¸Ñ Ñƒ пациентов группы COVID(+) ÑоÑтавил 5,4 Ð¼ÐµÑ (95% ДИ 5,1—5,7), у пациентов группы COVID(–) — 5,9 Ð¼ÐµÑ (95% ДИ 5,8—6,0) (χ² =5,27;p=0,0217). Умершие и выжившие ÑопоÑтавимы по полу и возраÑту (p>0,05). У пациентов Ñ Ð»ÐµÑ‚Ð°Ð»ÑŒÐ½Ñ‹Ð¼ иÑходом отмечены более низкие иÑходные Ð·Ð½Ð°Ñ‡ÐµÐ½Ð¸Ñ SpO2, гемоглобина, ÑкороÑти клубочковой фильтрации (СКФ), более выÑÐ¾ÐºÐ°Ñ Ð¾Ñ†ÐµÐ½ÐºÐ° в баллах по шкале Syntax Score, более выÑокий уровень С-реактивного белка, креатинина (p<0,05). Ð’ 72,2% (n=13) летальных Ñлучаев у пациентов в анамнезе отмечен COVID-19 (p=0,0554). У 72,2% (n=13) пациентов Ñ Ð»ÐµÑ‚Ð°Ð»ÑŒÐ½Ñ‹Ð¼ иÑходом наблюдалоÑÑŒ многоÑоÑудиÑтое поражение коронарных артерий (p<0,0001). При развитии ИМбпST в Ñрок до 28 дней от Ð·Ð°Ð±Ð¾Ð»ÐµÐ²Ð°Ð½Ð¸Ñ COVID-19 отмечалоÑÑŒ увеличение риÑка Ñ€Ð°Ð·Ð²Ð¸Ñ‚Ð¸Ñ Ð»ÐµÑ‚Ð°Ð»ÑŒÐ½Ð¾Ð³Ð¾ иÑхода (ОР33,2;p<0,0001). Предикторами Ñ€Ð°Ð·Ð²Ð¸Ñ‚Ð¸Ñ Ð»ÐµÑ‚Ð°Ð»ÑŒÐ½Ð¾Ð³Ð¾ иÑхода через 6 Ð¼ÐµÑ ÑвлÑлиÑÑŒ повышение титра IgG к SARS-CoV-2 ≥ 234,9 Ед/л, СРБ ≥ 17,3 мг/л, Ñнижение протромбинового времени < 9,5 Ñ, СКФ < 46,9 мл/мин/1,73 м² . Заключение. У пациентов, перенеÑших COVID-19, отмечена Ñ‚ÐµÐ½Ð´ÐµÐ½Ñ†Ð¸Ñ Ðº большей чаÑтоте летальных иÑходов в течение 6 меÑ. Развитие инфаркта миокарда без подъема Ñегмента ST в течение 28 дней от поÑÐ²Ð»ÐµÐ½Ð¸Ñ Ñимптомов COVID-19 ÑопровождалоÑÑŒÑущеÑтвенным увеличением шанÑов летального иÑхода в течение 6 меÑ. Значимое влиÑние на развитие риÑка Ñмерти в течени µ 6 Ð¼ÐµÑ Ð¾ÐºÐ°Ð·Ñ‹Ð²Ð°Ð»Ð¸ повышенные уровни С-реактивного белка и IgG к SARS-CoV-2, Ñнижение протромбинового времени и ÑкороÑти клубочковой фильтрации. (Russian) [ FROM AUTHOR] Copyright of Profilakticheskaya Meditsina is the property of Media Sphere Publishing House and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)
Full text:
Available
Collection:
Databases of international organizations
Database:
Academic Search Complete
Type of study:
Prognostic study
Topics:
Long Covid
Language:
Russian
Journal:
Profilakticheskaya Meditsina
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS